|
|
The
role of 3-step radioimmunotherapy (RIT) as adjuvant treatment in malignant
gliomas
Chiara Grana, Marco Chinol, Chris Robertson, Mirco
Bartolomei, Tommaso M De Pas, Giovanni Paganelli
European Institute of Oncology, Milano, Italy
In
a previous study we applied a 3-step avidin-biotin pretargeting approach to
target 90Y-biotin to the tumor in patients with recurrent high grade glioma.
The encouraging results obtained in this phase I-II study prompted us to apply
the same approach in an adjuvant setting, to evaluate
i) time to relapse and
ii) overall survival.
We enrolled 37 high grade glioma patients, 17 with grade III glioma and 20 with
glioblastoma, in a controlled open non-randomized study.
All patients received surgery and radiotherapy and were disease-free by
neuroradiological examinations.
Nineteen patients (treated) received also adjuvant treatment with
radioimmunotherapy.
In the treated glioblastoma patients, median disease-free interval was 28 months
(range=9-59); median survival was 33.5 months and one patient is still without
evidence of disease.
All 12 control glioblastoma patients died after a median survival from diagnosis
of eight months.
In the treated grade III glioma patients median disease-free interval was 56
months (range=15-60) and survival cannot be calculated as only two, within this
group, died.
Three-step radioimmunotherapy promises to have an important role as adjuvant
treatment in high grade gliomas, particularly in glioblastoma where it impedes
progression, prolonging time to relapse and overall survival.
A further randomized trial is justified.
© Copyright 2002
American
Society of Clinical Oncology
Source:
http://www.asco.org/ac/1,1003,_12-002324-00_18-002002-00_19-002084-00_29-00A-00_42-00ONeill-00_43-00-00_44-00-00_45-00
Author-00_46-00Title-00_47-00Title-00_48-00and-00_49-00and,00.asp?cat=CNS+Tumors&parent=CENTRAL+NERVOUS+SYSTEM+TUMORS
&returnpid=2323 |
